These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 24953475)
21. Maintenance therapy for multiple myeloma. McCarthy PL; Palumbo A Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886 [TBL] [Abstract][Full Text] [Related]
22. Hepatotoxicity as a rare but serious side effect of thalidomide. Levesque E; Bradette M Ann Hematol; 2009 Feb; 88(2):183-4. PubMed ID: 18665361 [No Abstract] [Full Text] [Related]
23. [Current treatment strategies with novel agents for multiple myeloma]. Tokuhira M Rinsho Ketsueki; 2011 Aug; 52(8):587-602. PubMed ID: 21897064 [No Abstract] [Full Text] [Related]
24. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Gay F; Mina R; Troia R; Bringhen S Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1517-27. PubMed ID: 23961770 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. Dao K; Chtioui H; Lu Y; Peer CJ; Figg WD; Pruijm M; Buclin T; Kissling S Am J Kidney Dis; 2017 Apr; 69(4):553-554. PubMed ID: 28063733 [No Abstract] [Full Text] [Related]
31. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. de la Rubia J; Roig M; Ibáñez A; García I; Vera JA; Aguilar C; del Campo R; González N; Martínez R; Palomera L; Picón I; Rodríguez JN; Sanz MA Eur J Haematol; 2010 Oct; 85(4):363-5. PubMed ID: 20662900 [No Abstract] [Full Text] [Related]
32. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681 [No Abstract] [Full Text] [Related]